Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats

• Published in: Domestic animal endocrinology 2014-10, Vol.49, p.14-19
• Main Authors: Nishii, N., Takashima, S., Iguchi, A., Murahata, Y., Matsuu, A., Hikasa, Y., Kitagawa, H.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animal Feed - analysis; Animals; Cats - blood; Cats - physiology; Esophagostomy; Feline; Female; Gastric Inhibitory Polypeptide - genetics; Gastric Inhibitory Polypeptide - metabolism; Glucagon-like peptide 1; Glucagon-Like Peptide 1 - blood; Glucagon-Like Peptide 1 - metabolism; Glucose - administration & dosage; Glucose - pharmacology; Glucose-dependent insulinotropic polypeptide; Incretin; Incretins - blood; Incretins - genetics; Incretins - metabolism; Male; Pyrazines - administration & dosage; Pyrazines - pharmacology; Sitagliptin; Sitagliptin Phosphate; Triazoles - administration & dosage; Triazoles - pharmacology
• ISSN: 0739-7240; 1879-0054
• DOI: 10.1016/j.domaniend.2014.04.006

We investigated the effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats. Six cats were used for the glucose administration experiment and 5 cats were used for the feeding experiment. Glucose administration through an esophagostomy tube increased plasma glucagon-like peptide 1 (GLP-1) concentrations by 6-fold, whereas plasma glucose-dependent insulinotropic polypeptide (GIP) concentrations did not change. Feeding increased both plasma GLP-1 concentrations by 1.5-fold and GIP concentrations by 4.6-fold. Sitagliptin was administered through an esophagostomy tube (25 and 50 mg per cat) in the glucose administration experiment and orally (25 mg per cat) in the feeding experiment. Sitagliptin treatment potentiated the GLP-1 response to glucose by 1.5-fold (P < 0.05). In addition, postprandial plasma GLP-1 concentration was higher by 2-fold when sitagliptin was administered (P < 0.05). In contrast, administration of sitagliptin did not affect plasma GIP concentrations after glucose administration or feeding. Sitagliptin enhanced insulin secretion following glucose administration by 1.5-fold (P < 0.05); however, it did not influence the plasma glucose concentration. Furthermore, sitagliptin had no effect on the postprandial plasma glucose and insulin concentrations. In conclusion, this study provides no evidence that sitagliptin is beneficial for management of feline diabetes mellitus.